Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs TKO Group Holdings Inc (TKO) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
TKO Group Holdings IncTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs TKO Group Holdings Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $296.08 (market cap $8.04B), while TKO Group Holdings Inc trades at $186.21 (market cap $13.84B). The key difference: TKO Group Holdings Inc is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.69% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOTKO
Market Cap
$8.04B$13.84B
Sector
HealthTechnology
52-Week High
$339.75$224.96
52-Week Low
$241.71$155.61
Enterprise Value
$7.85B$18.01B
Dividend Yield
1.69%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.

Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.

TKO Group Holdings Inc

TKO Group Holdings trades at $180.96, down 1.87% on the day, with mixed technical signals showing bearish moving averages but bullish oscillators. The company reported strong Q1 2026 earnings beat but missed Q3 and Q4 2025 expectations. Revenue grew to $4.74B in 2025 with net income of $195.4M, while 2026 projections show continued growth to $5.1B revenue. Recent developments include successful international events and an $800M share repurchase completion.

Wall Street maintains strong bullish sentiment with 89% buy ratings and $228 consensus price target, representing 26% upside. Key risks include execution on earnings guidance and competitive pressures in sports entertainment. The company's premium valuation (P/E 68.6) requires sustained growth delivery, while positive cash flow trends and dividend payments provide shareholder returns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About TKO Group Holdings Inc

TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.

Read more on TKO